- Home
- NRO vs GNFT Comparison
NRO vs GNFT Comparison
Compare NRO & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- GNFT
- Stock Information
- Founded
- NRO 2003
- GNFT 1999
- Country
- NRO United States
- GNFT France
- Employees
- NRO N/A
- GNFT N/A
- Industry
- NRO Finance/Investors Services
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRO Finance
- GNFT Health Care
- Exchange
- NRO Nasdaq
- GNFT Nasdaq
- Market Cap
- NRO 170.5M
- GNFT 179.7M
- IPO Year
- NRO N/A
- GNFT 2019
- Fundamental
- Price
- NRO $3.31
- GNFT $3.74
- Analyst Decision
- NRO
- GNFT Strong Buy
- Analyst Count
- NRO 0
- GNFT 1
- Target Price
- NRO N/A
- GNFT $13.00
- AVG Volume (30 Days)
- NRO 239.4K
- GNFT 9.9K
- Earning Date
- NRO 01-01-0001
- GNFT 09-19-2024
- Dividend Yield
- NRO 11.41%
- GNFT N/A
- EPS Growth
- NRO N/A
- GNFT N/A
- EPS
- NRO N/A
- GNFT 0.47
- Revenue
- NRO N/A
- GNFT $86,225,222.00
- Revenue This Year
- NRO N/A
- GNFT $145.20
- Revenue Next Year
- NRO N/A
- GNFT N/A
- P/E Ratio
- NRO N/A
- GNFT $7.89
- Revenue Growth
- NRO N/A
- GNFT 175.45
- 52 Week Low
- NRO $2.51
- GNFT $3.35
- 52 Week High
- NRO $3.45
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- NRO 38.13
- GNFT 49.41
- Support Level
- NRO $3.33
- GNFT $3.68
- Resistance Level
- NRO $3.45
- GNFT $4.03
- Average True Range (ATR)
- NRO 0.07
- GNFT 0.15
- MACD
- NRO -0.01
- GNFT 0.05
- Stochastic Oscillator
- NRO 5.56
- GNFT 57.35
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.